Meeting ReportOncology: Clinical Therapy and Diagnosis
PSMA PET imaging in metastatic castration-resistant prostate cancer patients treated with 177Lu-PSMA-617: correlation with response, progression free (PFS) and overall survival (OS)
Muhammad Junaid Niaz, Michael Sun, Myrto Skafida, Ana Molina, John Babich, Shankar Vallabhajosula, David Nanus, Charlene Thomas, Paul Christos, Neil Bander, Scott Tagawa and Joseph Osborne
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 191;
Muhammad Junaid Niaz
1Urology Weill Cornell Medical College New York NY United States
Michael Sun
2Medicine Weill Cornell Medical College New York NY United States
Myrto Skafida
3Molecular Imaging and Theraputics Weill Cornell Medical College New York NY United States
Ana Molina
2Medicine Weill Cornell Medical College New York NY United States
John Babich
3Molecular Imaging and Theraputics Weill Cornell Medical College New York NY United States
Shankar Vallabhajosula
1Urology Weill Cornell Medical College New York NY United States
David Nanus
2Medicine Weill Cornell Medical College New York NY United States
Charlene Thomas
4Biostatistics and Epidemiology Weill Cornell Medical College New York NY United States
Paul Christos
4Biostatistics and Epidemiology Weill Cornell Medical College New York NY United States
Neil Bander
1Urology Weill Cornell Medical College New York NY United States
Scott Tagawa
2Medicine Weill Cornell Medical College New York NY United States
Joseph Osborne
3Molecular Imaging and Theraputics Weill Cornell Medical College New York NY United States
In this issue
Journal of Nuclear Medicine
Vol. 61, Issue supplement 1
May 1, 2020
PSMA PET imaging in metastatic castration-resistant prostate cancer patients treated with 177Lu-PSMA-617: correlation with response, progression free (PFS) and overall survival (OS)
Muhammad Junaid Niaz, Michael Sun, Myrto Skafida, Ana Molina, John Babich, Shankar Vallabhajosula, David Nanus, Charlene Thomas, Paul Christos, Neil Bander, Scott Tagawa, Joseph Osborne
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 191;
PSMA PET imaging in metastatic castration-resistant prostate cancer patients treated with 177Lu-PSMA-617: correlation with response, progression free (PFS) and overall survival (OS)
Muhammad Junaid Niaz, Michael Sun, Myrto Skafida, Ana Molina, John Babich, Shankar Vallabhajosula, David Nanus, Charlene Thomas, Paul Christos, Neil Bander, Scott Tagawa, Joseph Osborne
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 191;
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.